CLINICAL TRIALS PROFILE FOR METHYLERGONOVINE MALEATE
✉ Email this page to a colleague
All Clinical Trials for METHYLERGONOVINE MALEATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00891150 ↗ | Oxytocin to Decrease Blood Loss During Cesarean Section | Completed | American University of Beirut Medical Center | N/A | 2012-07-01 | The goal of this study is to determine the best dose of a drug called oxytocin, that is usually used to stop bleeding during a delivery, when used during a cesarean delivery. It will be administered during cesarean section in order to decrease the amount blood loss. The investigators are proposing to have 3 groups of subjects each given a different safe dose of oxytocin and then to assess the effectiveness of each regimens on the amount blood lost during cesarean sections.This will let use know which is the best lowest dose needed. |
| NCT02408965 ↗ | Uterotonic Prophylaxis Trial | Completed | University of California, San Francisco | Phase 4 | 2015-03-01 | Excessive bleeding after dilation and evacuation (D&E) requiring interventions is common, occurring in approximately 30% of cases at one large abortion-providing clinic. Uterotonic prophylaxis at the time of D&E, particularly with methylergonovine maleate (MM), is a common practice among D&E providers despite nearly no evidence for its efficacy. Finding ways to decrease excessive bleeding after D&E has the potential both to improve patient safety and to reduce costs of provider-initiated interventions. The investigators propose a randomized, controlled trial to investigate the efficacy of MM prophylaxis versus placebo in decreasing excessive bleeding measured by a composite outcome among women undergoing D&E at 20 to 24 weeks. |
| NCT03303235 ↗ | Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections | Withdrawn | Johns Hopkins University | Early Phase 1 | 2020-07-01 | Insufficient uterine tone resulting in atony can potentiate hemorrhage and adverse outcomes for the parturient. Oxytocin is the first pharmacologic agent used, followed by methylergonovine, carboprost, and misoprostol. The American Congress of Obstetricians and Gynecologists (ACOG) recommends the sequential use of oxytocin, followed by methylergonovine, carboprost, misoprostol, then surgical intervention for cases of refractory uterine atony. Many studies have examined the effect and dosage of intravenous uterotonics, including oxytocin. Although there are anecdotal reports of using intravenous bolus or rapid infusion of methylergonovine, no randomized trial has compared efficacy and side effects of these two routes of administration. Investigators hypothesize that intravenous methylergonovine reduces the time to adequate uterine tone (the tone at which the uterus is adequately contracted to prevent atony after delivery of neonate), decreases the total dose of methylergonovine to contract the uterus, and therefore produces fewer side effects of hypertension, nausea, and vomiting. Reducing the time to achieve adequate uterine tone is likely to decrease postpartum hemorrhage. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for METHYLERGONOVINE MALEATE
Condition Name
Clinical Trial Locations for METHYLERGONOVINE MALEATE
Trials by Country
Clinical Trial Progress for METHYLERGONOVINE MALEATE
Clinical Trial Phase
Clinical Trial Sponsors for METHYLERGONOVINE MALEATE
Sponsor Name
